Vertex sets out goals for 2013

Vertex will continue with its research into cystic fibrosis, hepatitis C and autoimmune diseases this year.

Vertex Pharmaceuticals Incorporated enjoyed total revenues in 2012 of $1.53 billion, with net product revnues of $1.16 billion for its Incivek (teleprevir) and $171.6 million for its Kalydecotm (ivacaftor) treatments.
For the final quarter of the year, the pharma company reported total sales of $334 million, with $222.8 million of this figure attributed to Incivek and $58.5 million to Kalydeco.

Commenting on the firm's plans for the year ahead, Dr Jeffrey Leiden, chair, president and chief executive officer stated that Vertex will continue with its key development programmes and position itself for "sustainable long-term growth".

He said: "Entering 2013, we are committed to advancing key development programs and to maintaining financial strength to position the company for sustainable long-term growth."

The company intends to produce a large quantity of data this year from its programmes in cystic fibrosis, hepatitis C and autoimmune diseases. Dr Leiden added that Vertex will also start studies looking into transformative medicines for people with serious conditions.